Tasly: ​​Net profit attributable to parent company in the first quarter was 295 million yuan, a year-on-year increase of 11.58%

In the context of national policies that are favorable to traditional Chinese medicine, Tasly, a leading modern traditional Chinese medicine company, has seized development opportunities and has a good start in 2024. On the evening of April 25, the 2024 first quarter report released by Tasly (600535) showed that during the reporting period, the company achieved operating income of 2.049 billion yuan; net profit attributable to the parent company was 295 million yuan, a year-on-year increase of 11.58%, and the operating quality remained good. Tasly, which has firmly established its leading position in the research and development of traditional Chinese medicines, currently has as many as 9 innovative traditional Chinese medicines in Phase III clinical trials, which indicates that the company will gradually launch new products on the market in the next few years and continue to expand the company\’s business growth space.

In the context of national policies that are favorable to traditional Chinese medicine, Tasly, a leading modern traditional Chinese medicine company, has seized development opportunities and has a good start in 2024.
On the evening of April 25, the 2024 first quarter report released by Tasly (600535) showed that during the reporting period, the company achieved operating income of 2.049 billion yuan; net profit attributable to the parent company was 295 million yuan, a year-on-year increase of 11.58%, and the operating quality remained good.
Tasly, which has firmly established its leading position in the research and development of traditional Chinese medicines, currently has as many as 9 innovative traditional Chinese medicines in Phase III clinical trials, which indicates that the company will gradually launch new products on the market in the next few years and continue to expand the company\’s business growth space.
The announcement of the continued stability of the main business shows that the company\’s operating income in the first quarter reached 2.049 billion yuan, of which revenue from the pharmaceutical industry was 1.809 billion yuan.
The report shows that Tasly’s traditional Chinese medicine segment maintained growth in the first quarter, achieving revenue of 1.441 billion yuan.
The company\’s three major basic medicine products – Compound Danshen Dropping Pills, Qishen Yiqi Dropping Pills, and Yangxue Qingnao Granules (pills) performed well.
Revenue from chemical preparation drugs was 290 million yuan, a year-on-year increase of 11.67%.
According to the report, anti-tumor product revenue increased by 31.74% compared with the same period last year, mainly due to the increase in sales of Diqing during the reporting period, indicating that Diqing has shaken off the impact of centralized procurement and price cuts, and is expected to return to the growth track in the future.
The 2023 annual report of the R&D Empowerment Business Growth Company shows that Tasly has 9 innovative traditional Chinese medicines entering clinical phase III, ranking first in the industry in the number of phase III varieties.
Judging from the scale of the R&D pipeline, Tasly\’s modern traditional Chinese medicine pipeline has 25 products, of which 19 products are in the second and third phases of clinical research, ensuring its position as a leading enterprise in traditional Chinese medicine research and development.
Several brokerage research reports pointed out that this shows that Tasly is entering a period of sustained high production and is expected to gradually launch new products approved for marketing in the next few years.
According to a research report by SDIC Securities, Tasly has abundant reserves in its mid- to late-stage clinical R&D pipeline and is about to enter the batch realization stage.
Everbright Securities (rights protection) research report believes that the company’s innovative traditional Chinese medicine research and development is expected to have a bumper harvest.
This is due to the company\’s strong investment in the research and development of traditional Chinese medicine.
In 2023, Tasly invested 1.315 billion yuan in research and development, a year-on-year increase of 29.49%, accounting for 17.73% of the revenue of the pharmaceutical industry, ranking first in the industry.
According to Wind data, the company has invested a total of 4.503 billion yuan in R&D in the past five years, accounting for 13.32% of the pharmaceutical industry revenue, ranking first in the traditional Chinese medicine industry.
The company not only leads in quantity in the research and development of modern traditional Chinese medicine, but is also clinical value-oriented, focusing on major diseases and areas where clinical needs are urgently needed.
The company\’s 2023 financial report shows that the secondary development of the company\’s key varieties is rapidly advancing. Qishen Yiqi Dropping Pills has increased indications for diabetic nephropathy, Qishen Yiqi Dropping Pills has increased indications for heart failure, and Yangxue Xingnao Pills has increased indications for Alzheimer\’s disease ( Phase II clinical trials for AD) indications are currently enrolling.
The company is also actively exploring the fields of stroke, diabetic nephropathy, Alzheimer\’s disease (AD) and other major diseases, and has broad market prospects in the future.
(Source of the article: China Securities Journal·China Securities Network)

Like (0)
Previous April 25, 2024 8:00 pm
Next April 25, 2024 8:00 pm

Related posts

  • Yang Zhenjin: How to layout gold and silver when they are in shock. Today’s latest trend analysis and operational suggestions

    Market interpretation: On Thursday, April 25, during the Asian session, spot gold fluctuated within a narrow range. The price of gold stabilized above the 2,300 mark on Wednesday, closing at $2,315.80 per ounce. The risk premium caused by tensions in the Middle East has eased, and investors are paying close attention. U.S. economic data will be released later this week, which may provide clues on the path of the Federal Reserve to raise interest rates. Gold and silver markets are correcting as conflicts in the Middle East deescalate. The key question is whether these corrections will turn into a near-term downward price trend, thus signaling that a market top has occurred. Market focus has returned to economic reports and the Federal Reserve. If the inflation data is too hot, it will be more difficult for the Federal Reserve to cut interest rates. The main economic focus this week will be the first-quarter gross domestic product (GDP) data released on Thursday and the March personal consumption expenditures (PCE) price index due to be released on Friday. Previously released consumer price inflation…

    US stock news April 25, 2024
  • Xinlai Yingcai (300260.SZ): Net profit in the first quarter was 68.4988 million yuan, a year-on-year increase of 27.36%

    Gelonghui April 25丨Xinlai Yingcai (300260.SZ) announced the first quarter report of 2024. The operating income during the reporting period was 689 million yuan, a year-on-year increase of 7.84%; the net profit attributable to shareholders of the listed company was 68.4988 million yuan, a year-on-year increase of 68.4988 million yuan. An increase of 27.36%; the net profit attributable to shareholders of listed companies after deducting non-recurring gains and losses was 59.6327 million yuan, a year-on-year increase of 16.48%; basic earnings per share was 0.168 yuan.

    US stock news April 25, 2024
  • Everest Property & Casualty Insurance’s capital increase of 80 million yuan has been promoted for 9 months but has not yet been implemented. When will the Class C risk rating be removed?

    Log in to Sina Finance APP and search [Xinpi] to view more evaluation grades Source: Blue Whale Finance Since the first quarter of 2022, the comprehensive risk rating of Everest Property Insurance has been downgraded from B to Category C, and the solvency is not up to standard. (Picture source: Visual China) After the announcement of a change in registered capital was disclosed in July 2023, and the registered capital was planned to be changed from 1 billion yuan to 1.08 billion yuan, Everest Property & Casualty Insurance Co., Ltd. (hereinafter referred to as \”Everest Property & Casualty Insurance\”) ) There has been no news of progress on this matter. Nine months later, on April 24, the company disclosed another relevant announcement, but the content was not that the capital increase was approved, but that the board of directors reviewed and approved the \”Proposal on Review of the Supplementary Plan for the \”New Capital Plan\”\” , the original capital increase amount remains unchanged, and some matters are supplemented to promote the implementation of subsequent capital increase matters. At the same…

    US stock news April 25, 2024
  • Coca-Cola Japan announces price increase of up to nearly 20%

    Gelonghui, May 10 | According to CCTV Finance, affected by continued inflation, a large number of commodities in Japan have increased in price.

    US stock news May 10, 2024
  • Apple CEO Cook arrives in Vietnam and reveals that investment in “Vietnam Fruit Chain” has exceeded 100 billion

    Apple CEO Tim Cook posted a number of photos of “people in Vietnam” on social media: tasting Hanoi’s characteristic egg (yolk) coffee with musicians, and hanging out with film and television creators at the famous local Hoan Kiem Lake. Taking a photo with the iPhone’s rear camera. Obviously, as the head of a consumer electronics giant and a world-renowned supply chain guru, Cook’s visit to Vietnam is naturally related to the layout of the industrial chain. 400 trillion VND invested in the past five years Just when Cook arrived in Hanoi, Apple issued a statement on its official website in Vietnam, announcing that it would increase investment in Vietnam’s supply chain. According to data provided in the announcement, since 2019, Apple’s cumulative investment in Vietnam through supply chain partners has exceeded 400 trillion VND. (Note: The latest exchange rate of RMB against Vietnamese Dong is 3466.83, Apple’s investment in Vietnam is equivalent to more than 112 billion yuan) More importantly, Apple’s local investment is also accelerating. Also starting in 2019, the company’s annual investment in Vietnam has doubled. Currently, Vietnam’s…

    US stock news April 15, 2024